Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 21, 2013, Pages 8644-8649

  Mao, Ping ^a,b   Joshi, Kaushal ^a   Li, Jianfeng ^c   Kim, Sung Hak ^a,d   Li, Peipei ^a   Santana Santos, Lucas ^c   Luthra, Soumya ^c   Chandran, Uma R ^c   Benos, Panayiotis V ^c   Smith, Luke ^a   Wang, Maode ^b   Hu, Bo ^e   Cheng, Shi Yuan ^e   Sobol, Robert W ^c,f,g   Nakano, Ichiro ^a,h  

^a OHIO STATE UNIVERSITY   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Korea University   (South Korea)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer stem cell; Epithelial to mesenchymal transition; Glioblastoma; Glioblastoma multiforme; Proneural to mesenchymal transition

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A3; BIOLOGICAL MARKER; MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOMA; GLIOMA CELL; GLIOMA STEM CELL; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NERVE CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PRONEURAL CELL; PROTEIN EXPRESSION; RADIATION; RADIATION ATTENUATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

CANCER STEM CELL; EPITHELIAL-TO-MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME; PRONEURAL-TO-MESENCHYMAL TRANSITION;

ALDEHYDE DEHYDROGENASE; ANIMALS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GLYCOLYSIS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84878151308     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221478110     Document Type: Article

References (24)

1. Dunn GP, et al. (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8): 756-784.
2. Adamson C, et al. (2009) Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs 18(8): 1061-1083.
3. Haar CP, et al. (2012) Drug resistance in glioblastoma: A mini review. Neurochem Res 37(6): 1192-1200.
4. Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3): 157-173.
5. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1): 98-110.
6. Lai A, et al. (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2): 142-148.
7. Singh SK, et al. (2004) Identification of human brain tumour initiating cells. Nature 432(7015): 396-401.
8. Joo KM, et al. (2012) MET signaling regulates glioblastoma stem cells. Cancer Res 72(15): 3828-3838.
9. Guvenc H, et al. (2013) Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 19(3): 631-642.
10. Miyazaki T, et al. (2012) Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res 18(5): 1268-1280.
11. Lottaz C, et al. (2010) Transcriptional profiles of CD133+ and CD133- glioblastomaderived cancer stemcell lines suggest different cells of origin. Cancer Res 70(5): 2030-2040.
12. Günther HS, et al. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27(20): 2897-2909.
13. Bao S, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120): 756-760.
14. Nakano I, Chiocca EA (2011) Finding drugs against CD133+ glioma subpopulations. J Neurosurg 114(3):648-, discussion 648-650.
15. Huang EH, et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8): 3382-3389.
16. Carro MS, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279): 318-325.
17. Chakrabarti R, et al. (2012) Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol 14(11): 1212-1222.
18. Marcato P, Dean CA, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 10(9): 1378-1384.
19. Marcato P, et al. (2011) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29(1): 32-45.
20. Carpentino JE, et al. (2009) Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 69(20): 8208-8215.
21. Wolf A, et al. (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208(2): 313-326.
22. Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y (2008) Grading of brain glioma with 1-11C-acetate PET: Comparison with 18F-FDG PET. Nucl Med Biol 35(2): 171-176.
23. Lu KV, et al. (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1): 21-35.
24. Sturm D, et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4): 425-437.